Opening soon. Stay in the loop

goodmorrowJoin the opening list

Your GLP-1 options.

Understand the medication, the routine and the care behind it.

Updated Clinical review pending · Educational draft

The form

Injections and tablets

The routine

Weekly or daily, depending on the medicine.

The evidence

Evidence belongs to the exact product.

Compare the approved products and their own directions below.

Your options

Approved GLP-1 medication examples
MedicationHow you take itAverage weight loss in its main trial
Tirzepatide (Zepbound)Weekly injectionAbout 21% at the top dose over 72 weeks
Semaglutide (Wegovy)Weekly injectionAbout 15% over 68 weeks
Semaglutide (Wegovy)Daily tabletAbout 14% over 64 weeks
Orforglipron (Foundayo)Daily tabletAbout 11% at the top dose over 72 weeks

Trial averages include people who stopped early. Your result depends on the exact product, dose, duration and individual circumstances. See care and medication pricing for the separate costs.

Who these medications are for

Wegovy, Zepbound and Foundayo are approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea. Your clinician confirms that, reviews your history and labs, and decides what's right for you.

Semaglutide and tirzepatide aren't for anyone who is pregnant or planning to be, or who has a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

What care looks like here

  1. A free 15-minute call to see whether we're a fit.
  2. A 45-minute first visit in person, with baseline labs and a written plan.
  3. The lowest starting dose, stepping up about every four weeks, only when you're ready.
  4. A check-in every month, in person or by video, with the same clinician.
  5. An honest conversation about maintenance, because weight tends to return when people stop.

Side effects

The common ones are nausea, constipation, diarrhea and reflux, mostly while the dose is rising. A slower schedule fixes most of it. Rare but serious risks include pancreatitis and gallbladder problems, and your clinician will tell you exactly what to watch for.

Some of the weight lost on these drugs is muscle. We set a protein target and a strength plan from the first visit. See GLP-1 Plus.

What we don't do

We don't prescribe compounded copies of semaglutide or tirzepatide, and we don't offer retatrutide until it's approved. Here's why compounded GLP-1s are a bad bet now.

Questions people ask

How much does GLP-1 treatment cost at Goodmorrow?

Clinical care is planned at $149 a month. Medication is additional and quoted for your exact prescription. The first visit with baseline labs is a separate $199 fee. Follow-up labs, supplies and delivery may also add to the total.

Do you take insurance?

Goodmorrow is exclusively self-pay. We do not bill insurance for visits, labs or medication.

Which GLP-1 is best?

The one you can take consistently. Tirzepatide produced more weight loss than semaglutide head to head. The pills suit people who don't want injections. Your clinician will walk through the tradeoffs with you.

How long do I have to stay on it?

Weight tends to return when people stop, so most people should plan on long-term treatment, sometimes at a lower maintenance dose. We'll talk about that before you start, not after.

Sources

  1. Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
  2. Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021
  3. Research publicationOral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) New England Journal of Medicine, 2025
  4. Research publicationOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) New England Journal of Medicine, 2025
  5. Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
  6. Secondary sourceSemaglutide (Wegovy) prescribing information Novo Nordisk, Prescribing information checked October 6, 2026
  7. Manufacturer informationOrforglipron (Foundayo) prescribing information Eli Lilly, Prescribing information checked October 6, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list